Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Cancer letters - 28 May 2017

Burnett Joseph P, Lim Gi, Li Yanyan, Shah Ronak B, Lim Rebekah, Paholak Hayley J, McDermott Sean P, Sun Lichao, Tsume Yasuhiro, Bai Shuhua, Wicha Max S, Sun Duxin, Zhang Tao

Abstract excerpt

Triple negative breast cancer (TNBC) typically exhibits rapid progression, high mortality and faster relapse rates relative to other breast cancer subtypes. In this report we examine the combination of taxanes (paclitaxel or docetaxel) with a breast cancer stem cell (CSC)-targeting agent sulforaphane for use against TNBC. We demonstrate that paclitaxel or docetaxel treatment induces IL-6 secretion and results in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Docetaxel
Share to Interleukin-8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isothiocyanates

Share to Paclitaxel

Share to Taxoids

Share to Transcription Factor RelA

Share to Triple Negative Breast Neoplasms

Share to Tubulin Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 28254410
DOI: 10.1016/j.canlet.2017.02.023
PMCID: PMC8892390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.PMID 28254410Read ↗

Translational drugs targeting cancer stem cells in triple-negative breast cancerSemantic proximity Read ↗

An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancerSemantic proximity Read ↗

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBCSemantic proximity Read ↗

Signaling pathways essential for triple-negative breast cancer stem-like cellsSemantic proximity Read ↗

Selectively Targeting Breast Cancer Stem Cells By 8-Quinolinol and NiclosamideSemantic proximity Read ↗

Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factorsSemantic proximity Read ↗

Sulfatase 2 Inhibition Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy Through Augmentation of Extracellular ATPSemantic proximity Read ↗

Leveraging Synergy: The Therapeutic Potential of SN-38 and Immunotherapy in Breast and Prostate Cancer TreatmentSemantic proximity Read ↗

Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancerSemantic proximity Read ↗

Ganoderma lucidumextract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathwaySemantic proximity Read ↗

THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple‐Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.